Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement

Jennifer St. Sauver, Michael M. Lieber, Susan L Slager, Debra J. Jacobson, Michaela E. McGree, Steven J. Jacobsen

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

What's known on the subject? and What does the study add? Inflammatory processes may be associated with benign prostatic enlargement. Variants in the PTGS2 gene may increase the risk of prostate enlargement through increases in inflammatory processes. However, this increased risk may be minimized by use of nonsteroidal anti-inflammatory drugs (NSAIDs). OBJECTIVE • To determine if polymorphisms in the cyclooxygenase 2 (COX-2) enzyme gene (prostaglandin synthase 2; PTGS2) were associated with development of benign prostate enlargement (BPE), and whether associations were modified by use of nonsteroidal anti-inflammatory drugs (NSAIDs). MATERIALS AND METHODS • Participants were men residing in Olmsted County, MN, who were between 40 and 79 years of age in 1990 (N= 356). • Prostate volume was measured by transrectal ultrasound and men reported all the medications that they were taking at the time of the examination. Men were followed biennially for 16 years. • Ten tagging single nucleotide polymorphisms (SNPs) in the PTGS2 gene were typed using the Illumina GoldenGate TM Assay. • Associations between SNPs and development of BPE (volume >30 mL) were assessed by Cox proportional hazards models. Models were also stratified by NSAID use. RESULTS • We observed significant associations between four polymorphisms in the PTGS2 gene and development of BPE (all P < 0.05). • These associations were not observed among men who used NSAIDs. CONCLUSION • Variants in the PTGS2 gene may increase the risk of prostate enlargement, but the increased risk may be minimized by use of NSAIDs.

Original languageEnglish (US)
Pages (from-to)1610-1615
Number of pages6
JournalBJU International
Volume108
Issue number10
DOIs
StatePublished - Nov 2011

Fingerprint

Cyclooxygenase 2
Prostate
Anti-Inflammatory Agents
Enzymes
Genes
Pharmaceutical Preparations
Single Nucleotide Polymorphism
Prostaglandin-Endoperoxide Synthases
Proportional Hazards Models

Keywords

  • COX-2
  • prostate enlargement inflammation
  • PT6S2

ASJC Scopus subject areas

  • Urology

Cite this

Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement. / St. Sauver, Jennifer; Lieber, Michael M.; Slager, Susan L; Jacobson, Debra J.; McGree, Michaela E.; Jacobsen, Steven J.

In: BJU International, Vol. 108, No. 10, 11.2011, p. 1610-1615.

Research output: Contribution to journalArticle

St. Sauver, Jennifer ; Lieber, Michael M. ; Slager, Susan L ; Jacobson, Debra J. ; McGree, Michaela E. ; Jacobsen, Steven J. / Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement. In: BJU International. 2011 ; Vol. 108, No. 10. pp. 1610-1615.
@article{5ab6d84f969b458eb53c0fd6f395a2b4,
title = "Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement",
abstract = "What's known on the subject? and What does the study add? Inflammatory processes may be associated with benign prostatic enlargement. Variants in the PTGS2 gene may increase the risk of prostate enlargement through increases in inflammatory processes. However, this increased risk may be minimized by use of nonsteroidal anti-inflammatory drugs (NSAIDs). OBJECTIVE • To determine if polymorphisms in the cyclooxygenase 2 (COX-2) enzyme gene (prostaglandin synthase 2; PTGS2) were associated with development of benign prostate enlargement (BPE), and whether associations were modified by use of nonsteroidal anti-inflammatory drugs (NSAIDs). MATERIALS AND METHODS • Participants were men residing in Olmsted County, MN, who were between 40 and 79 years of age in 1990 (N= 356). • Prostate volume was measured by transrectal ultrasound and men reported all the medications that they were taking at the time of the examination. Men were followed biennially for 16 years. • Ten tagging single nucleotide polymorphisms (SNPs) in the PTGS2 gene were typed using the Illumina GoldenGate TM Assay. • Associations between SNPs and development of BPE (volume >30 mL) were assessed by Cox proportional hazards models. Models were also stratified by NSAID use. RESULTS • We observed significant associations between four polymorphisms in the PTGS2 gene and development of BPE (all P < 0.05). • These associations were not observed among men who used NSAIDs. CONCLUSION • Variants in the PTGS2 gene may increase the risk of prostate enlargement, but the increased risk may be minimized by use of NSAIDs.",
keywords = "COX-2, prostate enlargement inflammation, PT6S2",
author = "{St. Sauver}, Jennifer and Lieber, {Michael M.} and Slager, {Susan L} and Jacobson, {Debra J.} and McGree, {Michaela E.} and Jacobsen, {Steven J.}",
year = "2011",
month = "11",
doi = "10.1111/j.1464-410X.2011.10161.x",
language = "English (US)",
volume = "108",
pages = "1610--1615",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Associations between variants in the cyclooxygenase 2 enzyme gene (PTGS2) and development of benign prostate enlargement

AU - St. Sauver, Jennifer

AU - Lieber, Michael M.

AU - Slager, Susan L

AU - Jacobson, Debra J.

AU - McGree, Michaela E.

AU - Jacobsen, Steven J.

PY - 2011/11

Y1 - 2011/11

N2 - What's known on the subject? and What does the study add? Inflammatory processes may be associated with benign prostatic enlargement. Variants in the PTGS2 gene may increase the risk of prostate enlargement through increases in inflammatory processes. However, this increased risk may be minimized by use of nonsteroidal anti-inflammatory drugs (NSAIDs). OBJECTIVE • To determine if polymorphisms in the cyclooxygenase 2 (COX-2) enzyme gene (prostaglandin synthase 2; PTGS2) were associated with development of benign prostate enlargement (BPE), and whether associations were modified by use of nonsteroidal anti-inflammatory drugs (NSAIDs). MATERIALS AND METHODS • Participants were men residing in Olmsted County, MN, who were between 40 and 79 years of age in 1990 (N= 356). • Prostate volume was measured by transrectal ultrasound and men reported all the medications that they were taking at the time of the examination. Men were followed biennially for 16 years. • Ten tagging single nucleotide polymorphisms (SNPs) in the PTGS2 gene were typed using the Illumina GoldenGate TM Assay. • Associations between SNPs and development of BPE (volume >30 mL) were assessed by Cox proportional hazards models. Models were also stratified by NSAID use. RESULTS • We observed significant associations between four polymorphisms in the PTGS2 gene and development of BPE (all P < 0.05). • These associations were not observed among men who used NSAIDs. CONCLUSION • Variants in the PTGS2 gene may increase the risk of prostate enlargement, but the increased risk may be minimized by use of NSAIDs.

AB - What's known on the subject? and What does the study add? Inflammatory processes may be associated with benign prostatic enlargement. Variants in the PTGS2 gene may increase the risk of prostate enlargement through increases in inflammatory processes. However, this increased risk may be minimized by use of nonsteroidal anti-inflammatory drugs (NSAIDs). OBJECTIVE • To determine if polymorphisms in the cyclooxygenase 2 (COX-2) enzyme gene (prostaglandin synthase 2; PTGS2) were associated with development of benign prostate enlargement (BPE), and whether associations were modified by use of nonsteroidal anti-inflammatory drugs (NSAIDs). MATERIALS AND METHODS • Participants were men residing in Olmsted County, MN, who were between 40 and 79 years of age in 1990 (N= 356). • Prostate volume was measured by transrectal ultrasound and men reported all the medications that they were taking at the time of the examination. Men were followed biennially for 16 years. • Ten tagging single nucleotide polymorphisms (SNPs) in the PTGS2 gene were typed using the Illumina GoldenGate TM Assay. • Associations between SNPs and development of BPE (volume >30 mL) were assessed by Cox proportional hazards models. Models were also stratified by NSAID use. RESULTS • We observed significant associations between four polymorphisms in the PTGS2 gene and development of BPE (all P < 0.05). • These associations were not observed among men who used NSAIDs. CONCLUSION • Variants in the PTGS2 gene may increase the risk of prostate enlargement, but the increased risk may be minimized by use of NSAIDs.

KW - COX-2

KW - prostate enlargement inflammation

KW - PT6S2

UR - http://www.scopus.com/inward/record.url?scp=80155180593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80155180593&partnerID=8YFLogxK

U2 - 10.1111/j.1464-410X.2011.10161.x

DO - 10.1111/j.1464-410X.2011.10161.x

M3 - Article

C2 - 21481131

AN - SCOPUS:80155180593

VL - 108

SP - 1610

EP - 1615

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 10

ER -